Home » Advitech receives product licence for psoriasis treatment product Advitech Inc.

Advitech receives product licence for psoriasis treatment product Advitech Inc.

Related StoriesFDA accepts Sandoz regulatory submission for a proposed biosimilar etanerceptGuselkumab drug more effective than current standard of look after psoriasisPhase II psoriasis research shows efficacy of Boehringer Ingelheim's BI 655066 more than ustekinumab’The issuance of this NPN is significant for Advitech since it will allow the organization to distribute XP-828L/Dermylex in Canada and in many other countries in which a NPN is mandatory for the sign up of a Canadian Organic Health Item’ stated Michael Stangel, Chief and President Executive Officer of Advitech.Upon successful clinical advancement and regulatory approval, AbbVie will oversee commercial actions, with Galapagos retaining exclusive privileges in South and China Korea, and co-promotion privileges in its home nation of Belgium, and also the Luxembourg and Netherlands. The collaboration marks AbbVie’s second with Galapagos. The initial partnership targets developing GLPG0634, a selective JAK1 inhibitor, against arthritis rheumatoid .